Please login to the form below

CML

This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Novartis has been at the forefront of CML research for years – significantly changing the prognosis for patients. ... with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP).

Latest news

Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial

patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP). ... The US Food and Drug Administration (FDA) has already granted asciminib a fast track designation in CML.
Pfizer gets first FDA nod for hedgehog inhibitor in AML

indications such as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
Inside the patient-centricity bubble

There has been some egregious behaviour in the industry in terms of drug pricing,” he said referring to the net price of CML drugs, which have tripled over the course of
Pfizer’s leukaemia drug Mylotarg backed for use in EU

Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).
FDA’s year-end approvals take annual tally to 46

Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... It has become the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation

More from news
Approximately 5 fully matching, plus 49 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
Deal Watch January 2017

With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase
Deal Watch May 2016

In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and
Seismic shifts: Hepatitis C and payers

Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.
Deal Watch table for December 2014

Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

Helen Parfitt joins Research Partnership

She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Spotlight interview: 15 minutes on healthcare advertising

Marie Little, Managing Director, OPEN Health Patient &Brand Communications takes 15 minutes to answer some key questions on healthcare advertising. 1. WHAT IS HEALTHCARE ADVERTISING IN A NUTSHELL? Healthcare advertising follows the same principals
Spotlight interview: 15 minutes on patient-centricity in pharma

We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
Therapy Watch expands oncology and IBD portfolios

This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... US. CML is a rare cancer affecting the white blood
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017. .
Research Partnership

new Chronic Myelogenous Leukaemia (CML) study in the US.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Medical Editor: Competitive

Healthcare Senior Account Manager: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Account Director – Creative Healthcare Communications: Competative

Healthcare Account Director: Competitive

PMHub

Add my company

Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...